Tag: TG4010

Latest News

Transgene annonce l’inclusion du dernier patient de l’essai de Phase 2 avec TG4010 + Nivolumab + Chimiothérapie en 1ère ligne de traitement du cancer du poumon au stade avancé

Newsemia
STRASBOURG, France–(BUSINESS WIRE)–Regulatory News: Transgene (Paris:TNG), société de biotechnologie qui conçoit et développe des immunothérapies reposant sur des vecteurs viraux contre les cancers et les...
Latest News

Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)

Newsemia
STRASBOURG, France–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/TG4010?src=hash" target="_blank"gt;#TG4010lt;/agt;–Regulatory News: Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World